id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0326-0024,FDA,FDA-2011-N-0326,Recommendations for User Fee Programs: Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 Through 2017; Meeting,Notice,Public Meetings,2011-12-07T05:00:00Z,2011,12,2011-12-07T05:00:00Z,2012-01-07T04:59:59Z,2012-03-24T19:31:36Z,2011-31499,0,0,0900006480f7d578
FDA-2011-N-0326-0001,FDA,FDA-2011-N-0326,"Biologics Price Competition and Innovation Act of 2009: Options for User Fee Program for Biosimilar and Interchangeable Biological Product Applications, etc.",Notice,N-Notice,2011-05-10T04:00:00Z,2011,5,2011-05-10T04:00:00Z,2011-06-10T03:59:59Z,2011-06-14T18:18:42Z,2011-11348,0,0,0900006480c63210